Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:GRDX

Entero Therapeutics Q4 2025 Earnings Results & Report

$4.46 +0.21 (+4.94%)
Closing price 04:00 PM Eastern
Extended Trading
$4.59 +0.13 (+2.91%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Entero Therapeutics reported Q4 2025 earnings on May 1, 2026. The company reported EPS of -$1.88.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Entero Therapeutics EPS Results

Actual EPS
-$1.88
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Entero Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Entero Therapeutics Q4 2025 Earnings FAQ

Entero Therapeutics (NASDAQ:GRDX) reported earnings of -$1.88 per share for Q4 2025. The report was announced on Friday, May 1, 2026.

Entero Therapeutics Earnings Headlines

No headlines for this company have been tracked by MarketBeat.com
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entero Therapeutics and other key companies, straight to your email.

About Entero Therapeutics

Entero Therapeutics (NASDAQ:GRDX) is a clinical-stage biotechnology company focused on developing therapies for gastrointestinal disorders. The company’s work is centered on treatments intended to address unmet needs in conditions involving inflammation, immune responses and intestinal health.

Its lead development program is latiglutenase, an oral enzyme therapy designed to break down immunogenic gluten fragments in the digestive tract. The program is being developed for celiac disease, an autoimmune disorder triggered by gluten exposure. Entero Therapeutics has also pursued gastrointestinal drug candidates, including locally acting formulations intended to treat inflammatory diseases of the intestines.

The company’s activities are primarily focused on research and clinical development rather than the sale of marketed products. Its programs are intended for potential use in gastrointestinal conditions affecting patients in the United States and other international markets, subject to successful clinical development and regulatory approval.

View Entero Therapeutics Profile
Earnings Tools